Furthermore, cannabinoid and cannabinoid-like compounds can regulate EGCs activity, directly through PPARα receptors (PEA) and indirectly through PPARγ or CB2 receptors (under GI inflammatory conditions), exerting an anti-inflammatory effect that can be beneficial in IBD and, maybe, other types of GI pathologies displaying ENS inflammation (i.e., plexitis [252]). Here, PPARG is linked to inflammatory bowel disease.